SHANGHAI, Oct. 2, 2025 /PRNewswire/ — At Wonder Festival 2025, Assembly Character Toys brand Blokees launched its new “BLOKEES WHEELS” category, alongside three new model kit series: TERRAVENTURE, Fantastics Q and Serendipity Edition. The company also presented over 40 new model kits, making Blokees one of the most prominent highlights of the event.

The BLOKEES WHEELS category redefines small-scale buildable car models (1:64 scale). Through patented materials, global IP collaborations, and a dual “easy-to-assemble, easy-to-modify” design, Blokees establishes a new benchmark for interactive and customizable car model kits. Its debut product, the Transformers C series, the Batman E series, and Blokee’s original vehicle series, drew great attention at the exhibition.

The TERRAVENTURE is a new animal-themed model kits series launched by Blokees, which aims at teenagers and model enthusiasts. It focuses on legendary and rare creatures, combining assembly fun, articulated playability, and character collection.

At WF2025, Blokees unveiled its first TERRAVENTURE dinosaur series in collaboration with the globally renowned IP Jurassic World. With a precise scale, highly realistic biological textures, and 9–11 points of articulation, these models achieve both mobility and aesthetic quality, vividly embodying cinematic movements. This allows players to recreate iconic movie scenes and fully immerse themselves in a miniature “dinosaur capture adventure”.

The Fantastics Q series captures popular IPs like EVANGELION in a compact and adorable style, highlighting expressive details that resonate with anime and game fans. Meanwhile, the Serendipity Edition focuses on dynamic posing and customization, introducing 14cm MJD (Mechanically Jointed Doll) body with 19 points of articulation. Its outfit compatibility enables players to freely mix and match costumes, making it ideal for collectors of series like Hatsune Miku.

Blokees also presented over 40 model kits across major IPs such as Ultraman and Naruto. These products span multiple series, including Champion, Legend, daadoos, fully showcasing Blokees’ research and development capabilities and deep interpretation of global IPs. Notably, the exhibition featured an exclusive showcase of BFC creations, gathering outstanding works from international creators. This highlighted Blokees’ global influence and community-driven innovation in the model kit industry.

By advancing its “Universally appealing, Stepwise pricing, Globally promoting” strategy, Blokees continues to lead the evolution of China’s model kit industry and Pass on the Fun of Building.

Practical cleaning tips and exclusive product offers to keep homes fresh, cozy, and guest-ready this fall

SEATTLE, Oct. 2, 2025 /PRNewswire/ — As autumn settles in, homes everywhere face the familiar signs of the season — muddy entryways, dusty corners, and carpets in need of a refresh before the holidays arrive. Tineco, a global leader in intelligent home appliances, introduces its Autumn Cleaning Guide, designed to help households tackle seasonal messes with ease. By pairing practical cleaning tips with innovative technology, Tineco ensures that homes stay fresh, comfortable, and ready for every gathering this fall.

Seasonal Tips & Smart Solutions

Keep Entryways Tidy and Tools Fresh

Rain and leaves often end up at the front door. The FLOOR ONE S7 Stretch Ultra makes seasonal cleaning simple with its 180° lay-flat reach, dual-sided edge access, and a FlashDry heated self-cleaning system that dries the brush head for easier maintenance after every use.

Tip: A quick daily pass in high-traffic entry areas stops dirt and debris from spreading throughout the home.

Sanitize with the Power of Steam

Cooler months bring more time indoors — making hygiene especially important. Newly certified by TÜV for Bacteria Elimination and Pet-Friendly Cleaning, the FLOOR ONE S7 Stretch Steam harnesses 320°F HyperSteam Technology to break down stubborn grime, lift stuck-on messes, and sanitize without chemicals.

Tip: Focus on kitchens and play areas, where a clean environment matters most.

Elevate Living Spaces with Flagship Design

Seasonal gatherings bring friends and family together — and a spotlight on the home itself. The FLOOR ONE S9 Artist PRO, Tineco’s flagship model, combines full-performance floor care with an elegant, artist-inspired design. With edge-to-edge reach, smooth maneuverability, and an illuminated display, it leaves both floors and guests impressed.

Tip: Position the S9 Artist PRO in the living room — not only as a tool for spotless cleaning but also as a reflection of modern living quality and household style.

Smarter Stick Vacuuming, Simplified

For households that need the versatility of a traditional stick vacuum, the PURE ONE Station 5 offers 175W of powerful suction, a wide LED headlight, and most importantly, a 2.5L dustbin within its station for auto-emptying. Its full-path self-cleaning design ensures that every use feels like cleaning with a fresh machine.

Tip: Whether for daily floor care or reaching different areas of the home, the PURE ONE Station 5 makes effortless, all-around cleaning part of the routine.

Refresh Carpets for a Cozy Season

Carpets and rugs carry the weight of autumn — from leaves and mud to allergens. The CARPET ONE Cruiser refreshes with 130W of suction, intuitive SmoothPower technology, and quick-drying 167°F PowerDry performance. A convenient self-cleaning cycle keeps the machine ready for the next use.

Tip: Refresh high-traffic rugs and carpets weekly to maintain a healthier, more inviting home environment.

Prime Day Ready

Tineco’s exclusive Prime Day offers will begin on October 7, giving households the perfect opportunity to upgrade their cleaning routines ahead of the busy holiday season. Each featured product — including the FLOOR ONE S7 Stretch Ultra, FLOOR ONE S7 Stretch Steam, FLOOR ONE S9 Artist PRO, PURE ONE Station 5, and CARPET ONE Cruiser — will be available with limited-time savings during the event.

To learn more about Tineco and its full portfolio of intelligent stick vacuums, floor washers, carpet cleaners, and more, please visit us.tineco.com.

About Tineco

Tineco (“tin-co”) was founded in 1998 with its first product launch as a vacuum cleaner and, in 2019, pioneered the first-ever smart vacuum. Today, the brand has evolved into a global leader in intelligent appliances spanning floor care, kitchen, and personal care categories. With a growing user base of over 19.5 million households and availability in approximately 30 countries worldwide, Tineco remains committed to its brand vision of making life easier through smart technology and continuous innovation. For more information, visit us.tineco.com.

$75m funding round will fuel mission to protect financial institutions and consumers from fraud and scams

LISBON, Portugal, Oct. 2, 2025 /PRNewswire/ — Feedzai, the leading AI-native RiskOps platform for financial crime prevention, today announced it is valued at more than $2 billion following an investment round of approximately $75 million. The new funding adds new institutional investors Lince Capital, Iberis Capital, and Explorer Investments, with renewed backing from Oxy Capital and Buenavista Equity Partners.

“Fraud isn’t just numbers on a balance sheet. It’s families losing their life savings and businesses losing customers. Protecting people and organizations from financial crime is why we built Feedzai. It’s our steadfast mission to keep commerce safe,” said Nuno Sebastião, Co-Founder and CEO of Feedzai. “This new investment round enables us to continue driving innovation to defend against whatever comes next, so that every form of payment, even those yet to be imagined, can be trusted and adopted safely.”

Company Momentum

Feedzai’s evolution into a comprehensive financial crime prevention platform for fraud, risk, and anti-money laundering teams has fueled strong growth. Feedzai protects more than 70 billion in annualized payment volume across card transactions and bill payments.

The new investment follows a year of rapid growth and innovation marked by major milestones:

• Breakthrough products: Launched Feedzai Orchestration and Feedzai IQ, empowering financial institutions to make more intelligent, rapid, and precise risk assessments.

• Customer impact: Doubled outcomes to more than $2B in losses prevented and 20M+ analyst hours saved.

• Responsible AI leadership: Introduced the TRUST Framework, embedding responsible design into every facet of GenAI development so systems remain fair, explainable, and secure.

Multi-Product Platform for Fighting Financial Crime

The average financial institution uses disparate tools from up to a dozen different vendors to run its daily financial crime operations. This fragmented approach creates unnecessary complexity and inefficiency, especially as companies grow. Feedzai addresses this challenge by providing a comprehensive financial crime prevention solution that consolidates various point products into a single, modern platform and is increasingly powering more of the financial tech stack within companies as they transition from legacy systems to AI-native systems.

Feedzai’s platform has expanded to cover distinct financial institution product lines, including bank account openings, credit card transactions, transaction monitoring, payments, and more.

“Feedzai’s ability to execute across multiple product lines while scaling globally places them in the elite tier of software companies,” said Vasco Pereira Coutinho, CEO at Lince Capital. “Financial fraud is one of the defining risks of our time, and Feedzai combines proven technology with deep expertise to protect both banks and their customers. With its AI-driven, end-to-end approach to risk operations, Feedzai is uniquely positioned to transform the industry.”

Garrigues served as legal counsel to Feedzai on the recent investment round.

About Feedzai

Feedzai is the world’s first end-to-end financial crime prevention platform, protecting people and payments with AI-native solutions that stop fraud and financial crime. Leading financial institutions trust Feedzai to manage critical risk and compliance processes, safeguarding trillions of dollars of transactions while improving the customer experience and protecting the privacy of everyday users. For more information, users can visit feedzai.com.

Media contact:
PR@feedzai.com

• The AVTOZMA^® (tocilizumab-anoh) intravenous (IV) formulation was approved in January 2025 by the FDA to treat the same conditions as the reference product ACTEMRA^® (tocilizumab)
• AVTOZMA is Celltrion’s fifth immunology biologic and seventh biosimilar approved by the FDA
• This launch strengthens Celltrion’s immunology portfolio beyond tumor-necrosis factor (TNF)-alpha and interleukin (IL)-12 and 23 inhibitors, to include an IL-6 inhibitor, broadening coverage across multiple inflammatory pathways and addressing a wider spectrum of diseases and patient populations

INCHEON, South Korea, Oct. 2, 2025 /PRNewswire/ — Celltrion, Inc. today announced that AVTOZMA^® (tocilizumab-anoh) intravenous (IV) formulation is now available to patients in the United States.

AVTOZMA IV is approved for all same indications as the reference product Actemra^®  (tocilizumab), including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (PJIA), systemic juvenile idiopathic arthritis (SJIA), coronavirus disease (COVID-19) and cytokine release syndrome (CRS).^[1] AVTOZMA IV will be available in all the same formulations currently provided by ACTEMRA IV. The available presentations are 80 mg/4 mL (20 mg/mL), 200 mg/10 mL (20 mg/mL), 400 mg/20 mL (20 mg/mL) in single-dose vials.

“Immune-mediated conditions such as rheumatoid arthritis have profound impact on patients’ daily lives,” said Prof. Gerd-Rüdiger Burmester, MD, Professor of Medicine and Rheumatology, Senior Professor in the Department of Rheumatology and Clinical Immunology at Charité – Universitätsmedizin Berlin, Germany. “The availability of a tocilizumab biosimilar gives physicians additional options to manage the disease and maintain continuity of care, which is a welcome news for both patients and clinicians.”

“The launch of AVTOZMA IV reinforces Celltrion’s strong commitment to providing physicians and patients with access to high-quality treatment options for serious immune-mediated diseases and to supporting the sustainability of the U.S. healthcare system,” said Thomas Nusbickel, Chief Commercial Officer of Celltrion USA. “It also strengthens our immunology portfolio, expanding beyond TNF-α and IL-12/23 inhibitors, now including an IL-6 inhibitor, broadening coverage across inflammatory pathways and enhancing our ability to address a broader range of patient needs.”

At launch, AVTOZMA IV will be supported by a comprehensive patient support resources for healthcare providers and patients, and copay support for eligible commercial patients prescribed AVTOZMA IV.

Notes to Editors:

About AVTOZMA^® (CT-P47, tocilizumab-anoh)
AVTOZMA^® (tocilizumab-anoh), containing the active ingredient tocilizumab, is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist. Based on data from the global Phase III clinical trial designed to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of CT-P47 compared to reference tocilizumab, AVTOZMA received approval from the U.S. Food and Drug Administration (FDA) and European Commission (EC) in January and February 2025, respectively. In July 2025, the FDA approved an additional indication for the intravenous (IV) formulation of AVTOZMA for the treatment of cytokine release syndrome (CRS) in adult and pediatric patients aged two years and older. 

INDICATION 

AVTOZMA^® (tocilizumab-anoh) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of:

• Rheumatoid Arthritis (RA): Adult patients with moderately to severely active RA who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
• Giant Cell Arteritis (GCA): Adult patients with GCA.
• Polyarticular Juvenile Idiopathic Arthritis (pJIA): Patients 2+ years-old with active pJIA.
• Systemic Juvenile Idiopathic Arthritis (sJIA): Patients 2+ years-old with active sJIA.
• Cytokine Release Syndrome (CRS): Adults and pediatric patients 2+ years-old with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome
• COVID-19: Hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS INFECTIONS

AVTOZMA^® and other tocilizumab products may increase the risk of serious infections, potentially leading to hospitalization or death, especially in patients using concurrent immunosuppressants.

If a serious infection develops, interrupt AVTOZMA until the infection is controlled. Reported infections include:

• Active tuberculosis (TB) which may present with pulmonary or extrapulmonary disease. Test for latent TB before and during treatment (except in COVID-19 patients) and treat latent infections before starting AVTOZMA.
• Invasive fungal infections: Such as candidiasis, aspergillosis, and pneumocystis, may present as disseminated rather than localized disease.
• Opportunistic infections, including bacterial, viral and other opportunistic pathogens.

Monitor patients for signs of infection, including TB, during and after AVTOZMA treatment.
Contraindications: Known hypersensitivity to tocilizumab products.
Serious Infections. Serious and sometimes fatal infections have been reported with AVTOZMA. Do not use during active infections, including localized infections. Discontinue AVTOZMA if a serious infection occurs and resume only once controlled.

Gastrointestinal (GI) Perforation. Gastrointestinal perforations, often linked to diverticulitis, have been reported with tocilizumab. Use AVTOZMA cautiously in high-risk patients and promptly evaluate new abdominal symptoms for early detection and management.

Hepatotoxicity. Monitor for hepatic injury signs. Avoid AVTOZMA if ALT/ AST >1.5x ULN (RA/GCA) or >10x ULN (COVID-19); discontinue if ALT/AST >5x ULN or symptoms of liver disease develop.

Changes in Laboratory Parameters. Monitor neutrophils, platelets, liver enzymes, and lipids due to potential treatment-related changes; avoid initiating AVTOZMA in patients with critically low ANC or platelet counts.

Immunosuppression. The impact of AVTOZMA on malignancy development is unknown, but it may increase risk as an immunosuppressant.

Hypersensitivity Reactions, including anaphylaxis, and death, have occurred; administer IV infusions with anaphylaxis management support, discontinue permanently if reactions occur, and avoid use in patients with known hypersensitivity.

Demyelinating Disorders. The impact of tocilizumab on demyelinating disorders is unknown, but rare cases were reported; monitor symptoms and use caution with preexisting or recent disorders.

Active Hepatic Disease and Hepatic Impairment. Treatment with AVTOZMA is not recommended.

Live Vaccines. Avoid concurrent use with AVTOZMA.

Adverse Reactions (≥5%) include upper respiratory tract infections, nasopharyngitis, headache, hypertension, elevated ALT, and injection site reactions.

For more information, see Full Prescribing Information.

About Celltrion

Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world’s first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us and stay updated with our latest news and events on our social media – LinkedIn, Instagram, X, and Facebook.

About Celltrion USA

Celltrion USA is Celltrion’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion’s FDA-approved biosimilar products in immunology, oncology, hematology, and endocrinology include: INFLECTRA^® (infliximab-dyyb), TRUXIMA^® (rituximab-abbs), HERZUMA^® (trastuzumab-pkrb), VEGZELMA^® (bevacizumab-adcd), YUFLYMA^®(adalimumab-aaty), AVTOZMA^® (tocilizumab-anho), STEQEYMA^® (Ustekinumab-stba) STOBOCLO^® (denosumab-bmwo), OSENVELT^® (denosumab-bmwo), and OMLYCLO^® (omalizumab-igec), as well as the novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion’s unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit www.celltrionusa.com and stay updated with our latest news and events on our social media – LinkedIn.

FORWARD-LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as “prepares”, “hopes to”, “upcoming”, “plans to”, “aims to”, “to be launched”, “is preparing”, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, “anticipates”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries’ management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company’s business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements.

Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

Trademarks

AVTOZMA^® is a registered trademark of Celltrion Inc.
ACTEMRA^® is a registered trademark of Chugai Pharmaceutical Co., Ltd. 

References

For further information please contact:
Katie Gallagher
kgallagher@jpa.com
+1 617-657-1324

SEOUL, South Korea, Oct. 2, 2025 /PRNewswire/ — SurplusGLOBAL, a global leader in legacy semiconductor equipment and parts solutions, announced it will showcase the rapid growth of its www.SemiMarket.com platform and debut its new intelligent Atomic Layer Deposition (ALD) technology at SEMICON WEST 2025, October 7–9 at the Phoenix Convention Center.

Since its beta launch in June 2025, SemiMarket has surpassed 120,000 listings, is on track for 200,000 by year-end. The company is targeting 500,000 listings in 2026 and 1 million by 2027. The platform’s seller base has also expanded rapidly, with registrations growing 175% since June, reflecting global adoption and trust in SemiMarket as the industry’s most reliable source for legacy semiconductor parts. Ahead of its Grand Opening this December, SemiMarket is adding AI-driven services such as seller-friendly item recommendations, category suggestions, and customized event alerts to further enhance user experience and engagement.

By combining structured cataloging, valuation, and global trading, SemiMarket offers unmatched reliability and transparency for Fabs, OEMs, and buyers worldwide. The company emphasized that information credibility and data integrity remain central to the SemiMarket experience, ensuring customers can source legacy parts with confidence.

In addition to platform growth, SurplusGLOBAL will unveil its intelligent ALD solution, developed by retrofitting conventional furnace systems into Plasma-Enhanced ALD (PEALD) tools designed for mass production. The system integrates sub-100ms high-speed sensors and a built-in Fault Detection and Classification (FDC) module, unifying process and measurement data. By applying advanced algorithms for correlation modeling, anomaly detection, and predictive control, the equipment brings next-level intelligence and stability to deposition processes.

“SemiMarket’s rapid growth demonstrates the global demand for a trusted, transparent, and scalable marketplace for legacy equipment and parts. At the same time, our intelligent ALD solution shows how process innovation and legacy asset utilization can go hand in hand to bring new value to fabs and OEMs worldwide,” said Bruce Kim, CEO of SurplusGLOBAL.

SurplusGLOBAL will exhibit at booth #1629 throughout SEMICON WEST 2025. With the event debuting in Phoenix, the company aims to demonstrate how a robust global marketplace and next-generation intelligent process tools can address the semiconductor industry’s evolving challenges.

– Record-high competition ratio of 56:1… Winning dish “Kimpacho“ selected after final round among eight contestants

– Kimchi recipes from professional chefs to home cooks draw attention

SEOUL, South Korea, Oct. 2, 2025 /PRNewswire/ — Daesang’s kimchi brand ‘Jongga’, together with the prestigious U.S. culinary school ‘Institute of Culinary Education’ and SF Globalize, successfully concluded the ‘2025 Jongga Kimchi Cook Off’ in New York.

The Jongga Kimchi Cook Off is a global event held across the U.S., U.K., and France to showcase the appeal and excellence of kimchi worldwide. In the U.S., the competition has been co-hosted with the Institute of Culinary Education since 2020, drawing growing participation each year as contestants present increasingly diverse dishes featuring kimchi. This year, following successful events in France and the U.K., Daesang wrapped up the U.S. competition, further reinforcing Jongga’s standing as a leading global kimchi brand.

The U.S. round of the Jongga Kimchi Cook Off took place on the 30th (local time) at New York campus of the Institute of Culinary Education. This year’s contest featured the highest-ever competition rate of 56:1, with eight finalists selected to compete. Participants came from a wide range of backgrounds, including professional chefs, accountants, architects, and medical students, highlighting the strong interest in kimchi across the U.S. In particular, Steven Gao, a culinary influencer with 870,000 followers, joined as a special guest and presented recipes using Jongga’s U.S.-exclusive Sanhowon Kimchi and Cucumber(Oi) Kimchi, drawing significant attention.

The judging panel included Richard La Marita, Lead Chef-Instructor of Culinary Arts at ICE, and Samantha Landwehr, Chef-Instructor at ICE, with guest judge Chef Sungchul Shim, who runs a fine dining Korean restaurant in New York. The judges evaluated each dish based on creativity, artistry, and harmony with kimchi, supported by their deep expertise in Korean cuisine.

The grand prize went to chef Zofia Gallick from Brooklyn for her dish “Kimpacho,” a chilled soup made with Jongga Kimchi Sliced, tomato, cucumber, and jalapeño. The judges praised the dish for its vibrant flavors and textures. Second place went to Daniel Bologna for “Crispy Kimchi Jam Patty Melt,” third place to Onyinyechi Attah for “Kimchi Juice Ayo,” and the special Jongga Award was presented to Min Kyu Kim for “Cheung Fun Ssam.”

Lead Chef-Instructor Richard La Marita commented, “The level of entries this year was remarkably high. Many dishes showed a deep understanding of kimchi’s fermentation and used it in highly creative ways.” Guest judge Chef Sungchul Shim added, “I never expected to see such variety and sophistication in kimchi-based dishes here in the U.S. It was clear that kimchi is being embraced and integrated into local food culture as a new culinary genre.”

Oh Yeon-taek, Head of Daesang’s Kimchi CIC, stated, “The tremendous interest in this year’s competition reaffirmed that kimchi is becoming a familiar part of everyday life for American consumers. We will continue to promote Korean food globally through Jongga and O’food, ensuring people around the world can enjoy and connect with it.”

Currently, Jongga products are distributed in more than 80 countries worldwide, with the U.S. rising to the No.1 export market for Jongga kimchi since 2023. To meet rapidly growing demand, Jongga established a large-scale kimchi factory in Los Angeles in 2022, the first of its kind by a Korean food company, and has since been producing a variety of products tailored to local food culture. As the world’s No.1 packaged kimchi brand, Jongga is also actively expanding consumer touchpoints by hosting cooking competitions, participating in music festivals, and running food truck campaigns to showcase the excellence and versatility of kimchi to global audiences. 

About Daesang Corporation

Founded in 1956, Daesang Corporation has been one of the world’s largest producers of fermented food products for over 60 years, and has grown to be the global leading Korean based food company by operating global brands such as Jongga, and O’Food which provides sauce, ready-to-eat meals, and many more products. Headquartered in South Korea, the company has also manufacturing subsidiaries in United States, Poland, China, Indonesia, and Vietnam. Visit www.daesang.com/en for more information.